| Literature DB >> 33974197 |
B W Lamb1,2, S Miah3, T A Skolarus4,5, G D Stewart1,6, J S A Green7,8, N Sevdalis8, T Soukup9.
Abstract
BACKGROUND: Evidence-based tools are necessary for scientifically improving the way MTBs work. Such tools are available but can be difficult to use. This study aimed to develop a robust observational assessment tool for use on cancer multidisciplinary tumor boards (MTBs) by health care professionals in everyday practice.Entities:
Mesh:
Year: 2021 PMID: 33974197 PMCID: PMC8519835 DOI: 10.1245/s10434-021-09989-7
Source DB: PubMed Journal: Ann Surg Oncol ISSN: 1068-9265 Impact factor: 5.344
Overview of literature using the Metric for Observation of Decision-Making (MODe)
| Citation | Country | Tumor type | Use of MODe | Comments |
|---|---|---|---|---|
| Lamb et al. | UK | Urologic cancers | Development and validation of MODe; 5 meetings (112 cases) Observed by surgeon and psychologist IRR: 112 cases, ICC 0.31-0.87 | Scientific observational metrics can be reliably used by medical and non-medical observers in cancer MTBs to assess team decision-making. |
| Lamb et al. | UK | Urologic cancers | MODe observational assessment Cross validation with a 29-question self-report Observation of 164 cases in 5 MTBs 47 surveys from MTB members (response rate 70 %) | The quality of teamworking and clinical decision-making in MTBs can reliably be assessed using observational and self-report metrics. MTB members have good insight into their own team performance. |
| Lamb et al. | UK | Urologic cancers | MODe observational assessment Assessing effect of sequential MTB improvement interventions (e.g., MTBs checklist, MTB team training, and written guidance) Prospective longitudinal study: 16 months, 1421 patients | MODe can be used to evaluate the impact of QI interventions on MTB processes. |
| Jalil et al. | UK | Urologic cancers, colorectal cancer, skin cancer, upper gastrointestinal cancer, head and neck cancer | MODe observational assessment Refinement of MODe Validation of use for assessment of video-recorded cases 683 multidisciplinary tumor board case -332 cases (9 urology MDMs) by 1 urologist -224 cases (6 urology boards) by 2 urologists -127 video-recorded case discussions (5 tumor types, over 8 MDMs) IRR: 224 cases, ICC >0.7 | MODe scores correlate with decision efficacy. Video recordings offer a feasible, reliable method of assessing how MTBs work. MODe can be used across different tumor types Novice users can be trained to use MODe using video-recorded MTB meetings. |
| Shah et al. | UK | Colorectal cancer | Modification of MODe to cMDT-MODe for use in colorectal cancer MDMs cMDT-MODe observational assessment 267 cases across 11 MDMs at single institution IRR: 76 cases, ICC 0.79 (0.70-0.92) | MODe can be adapted for use in specific tumor types, in this case to cMDT-MODe for colorectal patients. |
| Hahlweg et al. | Germany | Dermatologic, gastrointestinal, gynecologic, head and neck, liver and biliary tract cancer, lymphoma and myeloma, neuro-oncologic, non-entity-specific oncologic, non-entity-specific surgical, thorax, and uro-oncologic cancer | MODe was adapted for use in German-speaking country MODe observational assessment 249 cases across 29 MTBs IRR: 39 cases, ICC.5 for all domains by end of study | MODe can be adapted for different languages and health care settings and provides reliable observational data. |
| Soukup et al. | UK | Breast cancer | MODe observational assessment Assessing effect of co-designed intervention bundle (meeting breaks, change of room layout, meeting chair) MTB with 15 members, 1335 patient reviews | MODe can be used as part of “team audit and feedback” to improve teamwork in cancer care. |
| Lumenta et al. | Austria | Mixed: not specified | MODe adapted to German language and culture as TB team performance assessment tool Clinical and nonclinical observers 244 patients in 27 MDMs IRR: cohorts of 11–141 cases, pairwise agreement 54–100 % | MODe was adapted to developed TB team performance tool in German-speaking country. Used to enabled the assessment of specialized multidisciplinary tumor boards with a special focus on teamwork patterns |
| Rosell et al. | Sweden | Rare cancers: multidisciplinary tumor boards for penile cancer, anal cancer, and vulvar cancer | MODe and MOT observational assessment Electronic survey of health professionals from 6 MDMs 67 case discussions observed 125/241 (52 %) responses to survey IRR: 76 cases, agreement 0.86 | MODe was used in a non-English-speaking health care setting. MODe can be used to assess video-conferenced MDT meetings. |
| Gandamihardja et al. | UK | Breast cancer | MODe observational assessment 10 MDMs (346 patients). IRR: 116 cases, ICC 0.73-0.93 | Breast cancer MTB evaluation via direct observation in a meeting is feasible and reliable. |
| Soukup et al. | UK | Breast cancer, colorectal cancer, gynaecologic cancer | Observational assessment of team behaviors using 3 tools: MODe, Bales Interaction Process Analysis (Bales IPA), Measure of Case-Discussion Complexity (MeDiC). 3 MTBs with 44 members. 30 meetings filmed, 822 case discussions | MODe can be used together with other behavioral assessment metrics to unravel sociocognitive predictors of team DM quality. MODe used in conjunction with MeDiC can provide stratified assessment of performance accounting for case mix. |
| Scott et al. | UK | Ovarian cancer | MODe adapted to gynaecologic oncology GO-MDT MODe GO-MODe observational assessment 223 MTB case discussions across 41 MDMs at 6 hospitals | MODe can be adapted for use in specific tumor types, in this case to GO-MODe for gynaecologic patients. |
| Soukup et al. | UK | Breast cancer, colorectal cancer, urologic cancer | MODe Observational assessment combined with exploratory factor analysis and regression analyses to assess predictors of treatment decision Non-clinical and clinical observers 4 teams observed, 1045 case discussions IRR: 273 cases; ICC = 0.71–0.92 | MODe can be used with other assessment tools to better understand the anatomy of MDT decsion making. |
MTB, multidisclinary tumor board; IRR, ICC, interclass correlation coefficient; MDM, cMDT, GO-MDT
Summary statistics for the MODe-Lite domainsa
| MODe-lite domain | M | SD | Mdn | IQR | Min | Max |
|---|---|---|---|---|---|---|
| Clinical input | 2.25 | 0.68 | 2 | 1 | 1 | 3 |
| Holistic input | 1.25 | 0.52 | 1 | 0 | 1 | 3 |
| Clinical collaboration | 1.76 | 0.76 | 2 | 1 | 1 | 3 |
| Pathology | 2.34 | 0.84 | 3 | 1 | 1 | 3 |
| Radiology | 2.15 | 0.96 | 3 | 2 | 1 | 3 |
| Management plan | 2.20 | 0.74 | 2 | 1 | 1 | 3 |
| Global score | 11.95 | 2.50 | 12 | 4 | 6 | 18 |
MODe, Metric for the Observation of Decision-making; MODe-Lite, user-friendly version of the MODe; M, mean; SD, standard deviation; Mdn, median; IQR, interquartile range; Min, minimum; Max, maximum
aScore range for the individual domains is 1 to 3, and for the global score it is 6 to 18. Higher scores indicate better quality. Note. Total (n = 146), breast (n = 40), colorectal (n = 31), gynecologic (n = 75)
Fig. 1.Copy of the MODe-LITE tool.
MODe-LITE Copyright 2021 © Soukup Lamb under CC-BY-NC-ND
Item convergent validity, reliability, and external validity for the MODe-Lite
| MODe-lite domain | MODe-Lite global score | MODe global score | MeDiC global score | ||||
|---|---|---|---|---|---|---|---|
| Clinical input | 146 | 0.60 | 0.001 | 0.41 | 0.001 | 0.12 | 0.159 |
| Holistic input | 146 | 0.58 | 0.001 | 0.43 | 0.001 | 0.39 | 0.001 |
| Clinical collaboration | 146 | 0.70 | 0.001 | 0.51 | 0.001 | 0.38 | 0.001 |
| Pathology | 146 | 0.25 | 0.002 | 0.12 | 0.149 | 0.03 | 0.740 |
| Radiology | 146 | 0.54 | 0.001 | 0.52 | 0.001 | 0.33 | 0.001 |
| Management plan | 146 | 0.77 | 0.001 | 0.44 | 0.001 | 0.25 | 0.003 |
| MODe-LITE global score | 146 | – | – | 0.71 | 0.001 | 0.41 | 0.001 |
MODe, Metric for the Observation of Decision-making; MODe-Lite, user-friendly version of the MODe; MeDiC, Measure of Case-Discussion Complexity; n, sample size; r, Pearson’s correlation; P, statistical significance value (P < 0.05)
External validity and internal consistency for MODe-Lite against the original MODe toola
| MODe item | ||||||||
|---|---|---|---|---|---|---|---|---|
| MODe-LITE domain | Cronbach’s alpha | |||||||
| Patient history | ||||||||
| Clinical input | 146 | 0.52 | 0.001 | 0.64 | ||||
| Psychosocial information | Comorbidity information | Patient views | ||||||
| Holistic input | 146 | 0.36 | 0.001 | 0.46 | 0.001 | 0.28 | 0.001 | 0.66 |
| Surgeon input | Oncologist input | Nurse input | ||||||
| Clinical collaboration | 146 | 0.21 | 0.012 | 0.48 | 0.001 | 0.45 | 0.001 | 0.58 |
| Radiologist input | Radiologist information | |||||||
| Radiology | 146 | 0.53 | 0.001 | 0.76 | 0.001 | 0.80 | ||
| Pathologist input | Pathology information | |||||||
| Pathology | 146 | 0.76 | 0.001 | 0.78 | 0.001 | 0.90 | ||
| Decision reached | ||||||||
| Management plan | 146 | 0.56 | 0.001 | 0.71 | ||||
MODe, Metric for the Observation of Decision-making; MODe-Lite, user-friendly version of the MODe; n, sample size; r, Pearson’s correlation; P, statistical significance value (P < 0.05)
aA traffic-light system for a visual guide was used to indicate how well each set of MODe items relates to its corresponding MODe-Lite domain: green represents good internal consistency, and amber represents fair internal consistency.
Inter-assessor reliability coefficients for the MODe-Lite domains
| MODe-Lite domain | Assessor 1 | Assessor 2 | Kappa | |||
|---|---|---|---|---|---|---|
| M | SD | M | SD | |||
| Clinical input | 60 | 1.98 | 0.73 | 1.95 | 0.77 | 0.64 |
| Holistic input | 60 | 1.20 | 0.48 | 1.25 | 0.54 | 0.89 |
| Clinical collaboration | 60 | 1.67 | 0.75 | 1.53 | 0.62 | 0.60 |
| Radiology | 60 | 2.00 | 0.97 | 1.95 | 0.99 | 0.85 |
| Pathology | 60 | 2.63 | 0.66 | 2.70 | 0.65 | 0.70 |
| Management plan | 60 | 2.03 | 0.74 | 1.82 | 0.77 | 0.97 |
| Global score | 60 | 11.52 | 2.50 | 11.20 | 2.45 | 0.84a |
MODe, Metric for the Observation of Decision-making; MODe-Lite, user-friendly version of the MODe; n, subsample size; M, mean; SD, standard deviation
aIntraclass correlation coefficient (ICC) values. Kappa coefficients can be interpreted as follows: 0.21–0.40 (fair agreement), moderate agreement (0.41–0.60), substantial agreement (0.61–0.80), almost perfect agreement (0.81–1.00).
Fig. 2.Schematic representing the phases of the multidisciplinary team working with application of quality-improvement tools. Reprinted with permission from43